Radioimmunotherapy of solid cancers: A review

Acta Oncologica

Volumn 35, Issue 3, 1996, Pages 343-355

  Kairemo, Kalevi J A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BISMUTH; IODINE 123; IODINE 125; IODINE 131; LUTETIUM; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM 186; RHENIUM 188; SAMARIUM 153; YTTRIUM 90;

BONE MARROW TOXICITY; BREAST CANCER; CANCER IMMUNOTHERAPY; COLORECTAL CARCINOMA; CONFERENCE PAPER; HUMAN; LUNG CANCER; OVARY CARCINOMA; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SOLID TUMOR;

EID: 0029929758     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609101651     Document Type: Conference Paper

References (92)

1. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colorectal carcinoma. J Nucl Med 1995; 36: 586-92.
2. 2 antibodies. Br J Cancer 1994; 70: 521-5.
3. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994; 12: 1561-71.
4. Sharkey RM, Goldenberg DM, Vagg R, et al. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. Cancer 1994; 73: 864-77.
5. Riva P, Tison V, Arista A, et al. Radioimmunotherapy of gastrointestinal cancer and glioblastomas. Int J Biol Markers 1993; 8: 192-7.
6. Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994; 12: 1193-203.
7. 131I-CC49 in colorectal cancer. Cancer 1994; 73: 1057-66.
8. 131I-chimeric B72.3 in metastatic colon cancer. J Nucl Med 1992; 33: 23-9.
9. Begent RHJ, Ledermann JA, Green AJ, et al. Antibody distribution and dosimetry in patients receiving radiolabeled antibody therapy for colorectal cancer. Br J Cancer 1989; 60: 406-12.
10. Schroff RW, Weiden PL, Appelbaum J, et al. Rhenium-186-labeled antibody in patients with cancer: Report of a pilot phase I study. Antibody Immunoconj Radiopharm 1990; 3: 99-110.
11. 186rhenium-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992; 33: 1099-112.
12. Weiden PL, Breitz HB, Seiler CA, et al. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. J Nucl Med 1993; 34: 2111-9.
13. Markoe AM, Brady LW, Woo D, et al. Treatment of gastrointestinal cancer using monoclonal antibodies. Front Radiat Ther Oncol, Vol. 24. Basel: Karger, 1990: 214-24.
14. DeNardo SJ, Warhoe KA, O'Grady LF, et al. Radioimmunotherapy for breast cancer: treatment of a patient with 1-131 L6 chimeric monoclonal antibody. Int J Biol Markers 1991; 6: 221-30.
15. Johnson TK, Gonzalez R, Kasliwal RK, et al. Distribution of a breast-directed I-131-labeled monoclonal antibody in blood and bone marrow: implications for radiation immunotherapy. Radiology 1992; 182: 107-14.
16. DeNardo SJ, Mirick GR, Kroger LA, et al. The biologic window for chimeric L6 radioimmunotherapy. Cancer 1994; 73: 1023-32.
17. 2 in experimental ovarian cancer. Eur J Nucl Med 1994; 21: 1183-90.
18. 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model. Acta Oncol 1993; 32: 801-5.
19. Maraveyas A, Snook D, Hird V, et al. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 1994; 73: 1067-75.
20. Jacobs AJ, Fer M, Su FM, et al. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical respose. Obstet Gynecol 1993; 82: 586-93.
21. Epenetos AA, Munro AJ, Stewart S. et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987; 5: 1890-9.
22. 131I radiotherapy. Br J Cancer 1988; 58: 658-62.
23. Stewart JS, Hird V, Snook D, et al. Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity. and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 1989; 16: 405-13.
24. Muto MG, Finkler NJ, Kassis AI. et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC 125. Gynecol Oncol 1992; 45: 265-72.
25. Buckman R, De Angelis C. Shaw P, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 1992; 45: 102-9.
26. Canevari S, Miotti S, Bottero F, Valota O, Colnaghi MI. Ovarian carcinoma therapy with monoclonal antibodies. Hybridoma 1993; 12: 501-7.
27. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403-6.
28. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium-111 labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991; 83: 97-104.
29. Larson SM, Carrasquillo JA, Krohn KA. et al. Localization of p97 specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 1983; 72: 2101-14.
30. Larson SM, Carrasquillo JA, McGuffin RW, et al. Use of 1-131-labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiology 1985; 155: 487-92.
31. Larson SM, Sgouros G, Cheung N-KV. Radioisotope conjugates. In: DeVita VT Jr, Hellman S. Rosenberg SA. eds: Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott Co., 1995: 534-52.
32. Lashford L, Jones D, Pritchard J, et al. Therapeutic application of radiolabeled monoclonal antibody UJ13A in children with disseminated neuroblastoma. NCI Monographs 1987; 3: 53-7.
33. Larson SM. Radioimmunology. Imaging and therapy. Cancer 1991; 67: 1253-60.
34. Schellhammer PF, Wright GL Jr. Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin North Am 1993; 20: 597-606.
35. Kairemo KJA, Liewendahl K. Radioimmunodetection of malignant solid tumours. Invited review. Scand J Clin Lab Invest 1994; 54: 569-83.
36. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994; 35: 1017-22.
37. Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 1993; 217: 149-54.
38. 131I-Hepama-1 mAb: preliminary results. J Cancer Res Clin Oncol 1993; 119: 257-9.
39. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50: 1039s-42s.
40. 131I anti-CEA: a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys 1987; 13: 687-95.
41. Order SE, Stillwagon GB, Klein JL, et al. Iodine-131-antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group Study. J Clin Oncol 1985; 3: 1573-82.
42. 90yttrium antiferritin: dose escalation and tumor dose. Antibody Immunoconj Radiopharm 1988; 1: 163-8.
43. Riva P, Arista A, Tison V, et al. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer 1994; 73: 1076-82.
44. Kalofonos HP, Pawlikowska TR, Hemingway A, et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989; 30: 1636-45.
45. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-24.
46. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with (1-131) anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65.
47. Press OW, Eary JF, Appelbaum FR, Bernstein ID. Radiolabeled antibody therapy of lymphomas. In De Vita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: JB Lippincott Co., 1995: 157-71.
48. Czuczman MS, Straus DJ, Divgi CR, et al. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 2021-9.
49. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 1993; 14: 587-95.
50. 131I-Lym-1. Cancer Res 1990; 50: 1014s-16s.
51. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD 37) antibody. J Clin Oncol 1989; 7: 1027-38.
52. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine-131-labeled anti-CD37 (MB-1) antibody in B-cell lymphoma. J Clin Oncol 1992; 10: 1696-711.
53. 131I LYM-1 monoclonal antibody. Antibody Immunoconj Radiopharm 1988; 1:17-33.
54. 131I-labeled LL2 (EPB-2) monoclonal antibody. J Clin Oncol 1991; 9: 548-64.
55. 131I-labeled monoclonal antibody: An Illinois Cancer Council study. J Clin Oncol 1987; 5: 562-73.
56. Lenhard RE, Order SE, Spunberg JJ, Asbell SO, Leibel SA. Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1296-300.
57. 90yttrium labeled antiferritin for refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 1989; 17: 815-21.
58. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pretargeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988; 29: 226-34.
59. Goldenberg DM, Sharkey RM, Ford E. Anti-antibody enhancement of iodine-131 anti-CEA radioimunodetection in experimental and clinical studies. J Nucl Med 1987; 28: 1604-10.
60. Dosio F, Magnani P, Paganelli G, Samuel A, Chiesa G, Fazio F. Three-step tumor pre-targeting in lung cancer immunoscintigraphy. J Nucl Biol Med 1993; 37: 228-32.
61. Guadagni F, Roselli M, Nieroda C, Dansky-Ullmann G, Schlom J, Greiner JW. Biological response modifiers as adjuvants in monoclonal antibody-based treatment (review). In Vivo 1993; 7: 591-9.
62. Vervoordeldonk SF, Merle PA, van Leeuwen EF, van der School CE, von dem Borne AE, Slaper-Cortenbach IC. Fc gamma receptor II (CD32) on malignant B cells influence modulation induced by anti-CD19 monoclonal antibody. Blood 1994; 83: 1632-9.
63. Dillman RO, Shawler DL, Dillman JB, Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2: 881-91.
64. Schroff RW, Morgan AC, Woodhouse CS, et al. Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization. J Biol Resp Modif 1987; 6: 457-72.
65. Traub UC, DeJager R, Primus FJ, Losman M, Goldenberg DM. Antiidiotype antibodies in cancer patients receiving monoclonal antibody carcinoembryonic antigen. Cancer Res 1988; 48: 4002-6.
66. 111In-labeled monoclonal antibody against prostatic acid phosphatase. Acta Oncol 1993; 32: 723-7.
67. Babaian RJ, Murray JL, Lamki LM, et al. Radioimmunological imaging of cancer with the use of indium-111-labeled monoclonal antibodies. J Urol 1987; 137: 439-43.
68. Weiden PL, Wolf SB, Breitz HB, et al. Human anti-mouse antibody suppression with cyclosporin A. Cancer 1994; 73: 1093-7.
69. Baum RP, Niesen A, Hertel A, et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994; 73: 1121-5.
70. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 1994; 73: 1425-32.
71. Buchsbaum DJ, Khazaeli MB, Davis MA, Lawrence TS. Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. Cancer 1994; 73: 999-1005.
72. 90Y-lymphoma therapy. Cancer 1994; 73: 966-73.
73. Griffith MH, Yorke ED, Wessels BW, DeNardo GL, Necay WP. Direct dose confirmation of quantitative autoradiogra-phy with micro-TLD measurements for radioimmunotherapy. J Nucl Med 1988; 29: 1795-809.
74. Leichner PK, Kwok CS. Tumor dosimetry in radioimmunotherapy: methods of calculations for beta particles. Med Phys 1993; 20: 529-34.
75. Strand S-E, Ljunggren K, Kairemo K, et al. Functional imaging and dosimetric applications of the beta camera in radioimmunodiagnosis and radioimmunotherapy. Antibody Immunoconj Radiopharm 1991; 4: 531-7.
76. Meredith RF, Johnson TK, Plott G, et al. Dosimetry of solid tumors. Med Phys 1993; 20: 583-92.
77. 111In-labeled monoclonal antibody in humans. Cancer Res 1987; 47: 3328-36.
78. Murase K, Kataoka M, Yauhara Y, et al. Monte Carlo estimates of absorbed dose rate in various tissues and organs. Eur J Nucl Med 1987; 13: 109-14.
79. 1311-9.2.27 monoclonal antibody in human malignant melanoma Cancer Res 1989; 49: 2783-9.
80. Sgouros G, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Modelling and dosimetry of monoclonal antibody M195 (Anti-CD33) in acute myelogenous leukemia. J Nucl Med 1993; 34: 422-30.
81. Strand S-E, Zanzonico P, Johnson TK. Pharmacokinetic modeling. Med Phys 1993; 20: 515-28.
82. Strand S-E, Jönsson B-A, Ljungberg M, Tennvall J. Radioimmunotherapy dosimetry. A review. Acta Oncol 1993; 32: 807-17.
83. Mausner LF, Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys 1993; 20: 503-10.
84. Bhargava KK, Acharya SA. Labeling of monoclonal antibodies with radionuclides. Semin Nucl Med 1989; 19: 187-201.
85. Kairemo KJA. Positron emision tomography of monoclonal antibodies. Acta Oncol 1993; 32: 825-30.
86. Prestwich WV, Nunes J, Kwok CS. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J Nucl Med 1989; 30: 1036-46.
87. Goddu S, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994; 35: 303-16.
88. Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus crossdose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med 1994; 35: 521-30.
89. Humm JL, Roeske JC, Fisher DR, Chen GTY. Microdosimetric concepts in radioimmunotherapy. Med Phys 1993; 20: 535-42.
90. Fisher DR. Radiation dosimetry for radioimmunotherapy. An overview of current capabilities and limitations. Cancer 1994; 73: 905-11.
91. Watson EE, Stabin MG, Siegel JA. MIRD formulation. Med Phys 1993; 20: 511-4.
92. Sgouros G, Chiu S, Pentlow KS, et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 1993; 34: 1595-601.